Interpace Biosciences, Inc. (IDXG)
USD 1.18
(-8.01%)
USD 1.18
(-8.01%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 28.15 Million USD | -64.38% |
| 2022 | 79.05 Million USD | -2.22% |
| 2021 | 80.84 Million USD | 8.13% |
| 2020 | 74.76 Million USD | 33.45% |
| 2019 | 56.02 Million USD | 261.36% |
| 2018 | 15.5 Million USD | 13.76% |
| 2017 | 13.62 Million USD | -61.33% |
| 2016 | 35.24 Million USD | -35.53% |
| 2015 | 54.67 Million USD | -42.92% |
| 2014 | 95.78 Million USD | 161.81% |
| 2013 | 36.58 Million USD | -14.55% |
| 2012 | 42.81 Million USD | -20.5% |
| 2011 | 53.85 Million USD | -1.86% |
| 2010 | 54.87 Million USD | 57.3% |
| 2009 | 34.88 Million USD | -16.8% |
| 2008 | 41.92 Million USD | 6.51% |
| 2007 | 39.36 Million USD | -24.93% |
| 2006 | 52.43 Million USD | -18.95% |
| 2005 | 64.69 Million USD | 9.14% |
| 2004 | 59.28 Million USD | -26.94% |
| 2003 | 81.13 Million USD | 19.8% |
| 2002 | 67.72 Million USD | -55.36% |
| 2001 | 151.73 Million USD | 14.85% |
| 2000 | 132.11 Million USD | 213.07% |
| 1999 | 42.2 Million USD | 89.24% |
| 1998 | 22.3 Million USD | 65.19% |
| 1997 | 13.5 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 26.74 Million USD | -5.01% |
| 2024 Q2 | 25.46 Million USD | -4.8% |
| 2023 FY | 28.15 Million USD | -64.38% |
| 2023 Q1 | 78.41 Million USD | -0.8% |
| 2023 Q3 | 76.93 Million USD | -1.56% |
| 2023 Q2 | 78.14 Million USD | -0.34% |
| 2023 Q4 | 28.15 Million USD | -63.4% |
| 2022 FY | 79.05 Million USD | -2.22% |
| 2022 Q2 | 83.44 Million USD | 0.9% |
| 2022 Q1 | 82.69 Million USD | 2.29% |
| 2022 Q3 | 76.88 Million USD | -7.85% |
| 2022 Q4 | 79.05 Million USD | 2.82% |
| 2021 Q4 | 80.84 Million USD | 2.39% |
| 2021 Q2 | 78.97 Million USD | 161.35% |
| 2021 Q3 | 78.95 Million USD | -0.03% |
| 2021 FY | 80.84 Million USD | 8.13% |
| 2021 Q1 | 30.21 Million USD | -59.58% |
| 2020 Q4 | 74.76 Million USD | 187.96% |
| 2020 Q3 | 25.96 Million USD | -66.17% |
| 2020 FY | 74.76 Million USD | 33.45% |
| 2020 Q1 | 25.13 Million USD | -55.13% |
| 2020 Q2 | 76.73 Million USD | 205.28% |
| 2019 Q2 | 19.5 Million USD | 4.79% |
| 2019 Q4 | 56.02 Million USD | 9.69% |
| 2019 Q1 | 18.61 Million USD | 20.04% |
| 2019 Q3 | 51.07 Million USD | 161.89% |
| 2019 FY | 56.02 Million USD | 261.36% |
| 2018 Q3 | 13.77 Million USD | 7.56% |
| 2018 FY | 15.5 Million USD | 13.76% |
| 2018 Q1 | 13.33 Million USD | -2.18% |
| 2018 Q2 | 12.8 Million USD | -3.96% |
| 2018 Q4 | 15.5 Million USD | 12.58% |
| 2017 FY | 13.62 Million USD | -61.33% |
| 2017 Q1 | 22.4 Million USD | -36.43% |
| 2017 Q3 | 14.01 Million USD | -19.47% |
| 2017 Q2 | 17.4 Million USD | -22.33% |
| 2017 Q4 | 13.62 Million USD | -2.74% |
| 2016 Q4 | 35.24 Million USD | -25.71% |
| 2016 FY | 35.24 Million USD | -35.53% |
| 2016 Q3 | 47.44 Million USD | -0.16% |
| 2016 Q2 | 47.51 Million USD | -1.96% |
| 2016 Q1 | 48.46 Million USD | -11.35% |
| 2015 Q2 | 97.27 Million USD | 1.34% |
| 2015 Q3 | 93.42 Million USD | -3.96% |
| 2015 Q4 | 54.67 Million USD | -41.48% |
| 2015 FY | 54.67 Million USD | -42.92% |
| 2015 Q1 | 95.98 Million USD | 0.21% |
| 2014 Q1 | 34.04 Million USD | -6.96% |
| 2014 Q4 | 95.78 Million USD | 160.26% |
| 2014 FY | 95.78 Million USD | 161.81% |
| 2014 Q3 | 36.8 Million USD | 22.24% |
| 2014 Q2 | 30.1 Million USD | -11.55% |
| 2013 Q1 | 44.91 Million USD | 4.9% |
| 2013 FY | 36.58 Million USD | -14.55% |
| 2013 Q2 | 39.56 Million USD | -11.92% |
| 2013 Q4 | 36.58 Million USD | -1.67% |
| 2013 Q3 | 37.2 Million USD | -5.95% |
| 2012 Q4 | 42.81 Million USD | -8.69% |
| 2012 FY | 42.81 Million USD | -20.5% |
| 2012 Q3 | 46.89 Million USD | 4.02% |
| 2012 Q2 | 45.08 Million USD | -8.68% |
| 2012 Q1 | 49.36 Million USD | -8.34% |
| 2011 Q4 | 53.85 Million USD | -1.49% |
| 2011 Q3 | 54.67 Million USD | 14.78% |
| 2011 Q1 | 52.02 Million USD | -5.19% |
| 2011 Q2 | 47.63 Million USD | -8.45% |
| 2011 FY | 53.85 Million USD | -1.86% |
| 2010 FY | 54.87 Million USD | 57.3% |
| 2010 Q4 | 54.87 Million USD | 27.2% |
| 2010 Q2 | 39.52 Million USD | 20.53% |
| 2010 Q3 | 43.14 Million USD | 9.16% |
| 2010 Q1 | 32.79 Million USD | -6.01% |
| 2009 Q1 | 31.57 Million USD | -24.69% |
| 2009 Q3 | 31.78 Million USD | 12.47% |
| 2009 Q4 | 34.88 Million USD | 9.77% |
| 2009 FY | 34.88 Million USD | -16.8% |
| 2009 Q2 | 28.25 Million USD | -10.51% |
| 2008 Q4 | 41.92 Million USD | 26.16% |
| 2008 Q2 | 33.85 Million USD | 4.2% |
| 2008 FY | 41.92 Million USD | 6.51% |
| 2008 Q1 | 32.48 Million USD | -17.47% |
| 2008 Q3 | 33.23 Million USD | -1.82% |
| 2007 Q1 | 42.46 Million USD | -19.02% |
| 2007 Q4 | 39.36 Million USD | 3.67% |
| 2007 Q3 | 37.97 Million USD | -5.31% |
| 2007 Q2 | 40.09 Million USD | -5.57% |
| 2007 FY | 39.36 Million USD | -24.93% |
| 2006 Q3 | 56.3 Million USD | -2.55% |
| 2006 FY | 52.43 Million USD | -18.95% |
| 2006 Q2 | 57.78 Million USD | -2.43% |
| 2006 Q4 | 52.43 Million USD | -6.87% |
| 2006 Q1 | 59.22 Million USD | -8.46% |
| 2005 FY | 64.69 Million USD | 9.14% |
| 2005 Q4 | 64.69 Million USD | 4.86% |
| 2005 Q3 | 61.69 Million USD | 13.47% |
| 2005 Q2 | 54.37 Million USD | 7.28% |
| 2005 Q1 | 50.68 Million USD | -14.5% |
| 2004 Q4 | 59.28 Million USD | -0.53% |
| 2004 Q3 | 59.59 Million USD | -14.78% |
| 2004 Q2 | 69.93 Million USD | -14.29% |
| 2004 Q1 | 81.59 Million USD | 0.57% |
| 2004 FY | 59.28 Million USD | -26.94% |
| 2003 Q4 | 81.13 Million USD | 23.29% |
| 2003 Q2 | 58.52 Million USD | -4.64% |
| 2003 FY | 81.13 Million USD | 19.8% |
| 2003 Q1 | 61.36 Million USD | -9.39% |
| 2003 Q3 | 65.8 Million USD | 12.45% |
| 2002 Q2 | 56.78 Million USD | -51.57% |
| 2002 Q1 | 117.24 Million USD | -22.73% |
| 2002 FY | 67.72 Million USD | -55.36% |
| 2002 Q4 | 67.72 Million USD | -5.01% |
| 2002 Q3 | 71.3 Million USD | 25.56% |
| 2001 Q2 | 158.24 Million USD | 0.84% |
| 2001 FY | 151.73 Million USD | 14.85% |
| 2001 Q4 | 151.73 Million USD | -5.98% |
| 2001 Q1 | 156.92 Million USD | 18.78% |
| 2001 Q3 | 161.39 Million USD | 1.99% |
| 2000 Q4 | 132.11 Million USD | 145.84% |
| 2000 FY | 132.11 Million USD | 213.07% |
| 2000 Q1 | 51.03 Million USD | 20.93% |
| 2000 Q2 | 55.5 Million USD | 8.76% |
| 2000 Q3 | 53.74 Million USD | -3.18% |
| 1999 Q4 | 42.2 Million USD | 43.54% |
| 1999 Q3 | 29.4 Million USD | -19.67% |
| 1999 FY | 42.2 Million USD | 89.24% |
| 1999 Q2 | 36.6 Million USD | 7.33% |
| 1999 Q1 | 34.1 Million USD | 52.91% |
| 1998 Q1 | 20.6 Million USD | 52.59% |
| 1998 Q3 | 18.9 Million USD | -7.35% |
| 1998 Q4 | 22.3 Million USD | 17.99% |
| 1998 Q2 | 20.4 Million USD | -0.97% |
| 1998 FY | 22.3 Million USD | 65.19% |
| 1997 FY | 13.5 Million USD | 0.0% |
| 1997 Q4 | 13.5 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | -680.405% |
| Arrayit Corporation | 7.49 Million USD | -275.597% |
| Atlantic International Corp. | 3.82 Million USD | -635.435% |
| Biocept, Inc. | 22.01 Million USD | -27.911% |
| Bioqual, Inc. | 18.93 Million USD | -48.68% |
| CardioGenics Holdings Inc | 1.79 Million USD | -1468.702% |
| DermTech, Inc. | 64.75 Million USD | 56.518% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 96.169% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | -127.33% |
| iMD Companies, Inc. | 1.67 Million USD | -1581.802% |
| IDenta Corp. | 1.01 Million USD | -2679.132% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -9350.338% |
| InVitro International | 78.99 Thousand USD | -35546.284% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | -42.719% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -21676.994% |
| Medical Imaging Corp. | 9.51 Million USD | -195.857% |
| NovelStem International Corp. | 4.2 Million USD | -569.436% |
| Optigenex Inc. | 9.57 Million USD | -194.202% |
| PharmChem, Inc. | 558.64 Thousand USD | -4940.213% |
| Proteome Sciences plc | 18.48 Million USD | -52.29% |
| Response Genetics, Inc | 15.86 Million USD | -77.456% |
| Rennova Health, Inc. | 49.66 Million USD | 43.309% |
| RushNet, Inc. | 6.23 Million USD | -351.307% |
| ScreenPro Security Inc. | 1.6 Million USD | -1659.167% |
| Stella Diagnostics Inc. | 18 Million USD | -56.381% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | -243.211% |
| Todos Medical Ltd. | 50.15 Million USD | 43.862% |